Developing early-phase oncology programs involves navigating and overcoming various challenges.
This week's Fierce Biotech is brought to you by Premier Research. Trouble viewing? Click here.
Dear E,
Developing early-phase oncology programs involves navigating and overcoming various challenges. However, biotech and specialty pharma sponsors do not need to tackle these complexities alone. Discover actionable insights to optimize your development strategies in our latest white paper.
In this white paper, we explore the many aspects a company must consider in planning and executing an early-phase oncology trial, from performing a regulatory gap analysis and developing a target product profile to identifying the right patients and selecting efficacy endpoints.
Read this white paper and delve into a hypothetical development scenario of a novel oncology compound, complete with key milestones for success and invaluable insights for your product development journey.
